Literature DB >> 9109763

Immunologic mechanisms of uveitis. New targets for immunomodulation.

S M Whitcup1, R B Nussenblatt.   

Abstract

The uvea consists of the choroid, ciliary body, and iris, and inflammation of the uveal tract is termed uveitis. Nevertheless, uveitis is commonly used to more generally describe intraocular inflammation involving not only the uvea, but also the retina, vitreous, and sclera. Fifty years ago, infectious organisms such as syphilis and tuberculosis were thought to be the cause of most forms of uveitis. Since that time, many causes of uveitis have been described as infectious and noninfectious. Scientists have shown that the immune response plays a critical role in the development of infectious and noninfectious forms of the disease. With a more detailed understanding of the immune mechanisms leading to the development of uveitis, we are now able to develop new therapeutic approaches based on targeting various components of the immune response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109763     DOI: 10.1001/archopht.1997.01100150522013

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  10 in total

Review 1.  Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management.

Authors:  Rajen Gupta; Philip I Murray
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Influence of Yanyankang Powder on Th1/Th2 in rats with experimental autoimmune uveitis.

Authors:  Qing-mei Tian; Hong-sheng Bi; Yan Cui; Jian-feng Wu; Xiao-feng Xie; Jun-guo Guo; Da-dong Guo; Ji-cun Qian
Journal:  Chin J Integr Med       Date:  2015-07-01       Impact factor: 1.978

3.  The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet's uveitis.

Authors:  H G Yu; D S Lee; J M Seo; J K Ahn; Y S Yu; W J Lee; H Chung
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

4.  Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells.

Authors:  Lizette M Cortes; Dody Avichezer; Phyllis B Silver; Dror Luger; Mary J Mattapallil; Chi-Chao Chan; Rachel R Caspi
Journal:  J Leukoc Biol       Date:  2008-05-21       Impact factor: 4.962

5.  An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.

Authors:  B M Segal; B K Dwyer; E M Shevach
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

6.  Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.

Authors:  Pedro Henrique Papotto; Eliana Blini Marengo; Luiz Roberto Sardinha; Karina Inácio Carvalho; Ana Eduarda Zulim de Carvalho; Sheyla Castillo-Mendez; Carina Calixto Jank; Bernard Vanhove; Anna Carla Goldberg; Luiz Vicente Rizzo
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

7.  Administration of Mycobacterium leprae rHsp65 aggravates experimental autoimmune uveitis in mice.

Authors:  Eliana B Marengo; Alessandra Gonçalves Commodaro; Jean Pierre S Peron; Luciana V de Moraes; Fernanda C V Portaro; Rubens Belfort; Luiz Vicente Rizzo; Osvaldo Augusto Sant'Anna
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

8.  Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems.

Authors:  Marcelo L Occhiutto; Fatima R Freitas; Raul C Maranhao; Vital P Costa
Journal:  Pharmaceutics       Date:  2012-05-14       Impact factor: 6.321

Review 9.  Immunotherapeutic strategies in autoimmune uveitis.

Authors:  Pedro Henrique Papotto; Eliana Blini Marengo; Luiz Roberto Sardinha; Anna Carla Goldberg; Luiz Vicente Rizzo
Journal:  Autoimmun Rev       Date:  2014-05-12       Impact factor: 9.754

10.  The small tellurium-based compound SAS suppresses inflammation in human retinal pigment epithelium.

Authors:  Rima Dardik; Tami Livnat; Gilad Halpert; Shayma Jawad; Yael Nisgav; Shirley Azar-Avivi; Baoying Liu; Robert B Nussenblatt; Dov Weinberger; Benjamin Sredni
Journal:  Mol Vis       Date:  2016-05-28       Impact factor: 2.367

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.